[Form 4] Aclaris Therapeutics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Aclaris Therapeutics’ Chief Business Officer James Loerop received new equity awards dated February 2, 2026. He was granted 97,700 restricted stock units, each representing one future share of common stock, and 341,900 employee stock options with a $3.61 exercise price.

The RSUs vest in four equal annual installments on the first through fourth anniversaries of February 2, 2026, contingent on continued service. The stock options also vest in four equal annual installments over the same schedule, becoming exercisable as service-based vesting conditions are met.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Loerop James

Role Chief Business Officer

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Units	97,700	$0.00	--
Grant/Award	Employee Stock Option (Right to Buy)	341,900	$0.00	--

Holdings After Transaction: Restricted Stock Units — 97,700 shares (Direct); Employee Stock Option (Right to Buy) — 341,900 shares (Direct)

Footnotes (1)

1. Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 2, 2026, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date. Exercisable with respect to 25% of the shares subject to the option vesting in four equal installments on the first, second, third and fourth anniversaries of February 2, 2026, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Loerop James

(Last) (First) (Middle)

C/O ACLARIS THERAPEUTICS, INC.

701 LEE ROAD, SUITE 103

(Street)

WAYNE PA 19087

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Aclaris Therapeutics, Inc. [ ACRS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Business Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	02/02/2026		A		97,700		(2)	(2)	Common Stock	97,700	$0	97,700	D
Employee Stock Option (Right to Buy)	$3.61	02/02/2026		A		341,900		(3)	02/01/2036	Common Stock	341,900	$0	341,900	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.

2. The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 2, 2026, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date.

3. Exercisable with respect to 25% of the shares subject to the option vesting in four equal installments on the first, second, third and fourth anniversaries of February 2, 2026, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date.

	/s/ Matthew Rothman, Attorney-in-Fact	02/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Aclaris Therapeutics (ACRS) report for James Loerop?

Aclaris reported that Chief Business Officer James Loerop received equity awards on February 2, 2026. He was granted 97,700 restricted stock units and 341,900 employee stock options, both reported as directly owned following the transactions.

How many restricted stock units were granted to Aclaris (ACRS) executive James Loerop?

James Loerop received 97,700 restricted stock units. Each unit represents a contingent right to receive one share of Aclaris common stock, subject to vesting conditions tied to his continued service with the company over time.

What stock option grant did Aclaris (ACRS) make to its Chief Business Officer?

Aclaris granted James Loerop 341,900 employee stock options on February 2, 2026. These options carry a $3.61 exercise price per share and are reported as directly owned derivative securities following the transaction.

What is the vesting schedule for James Loerop’s Aclaris (ACRS) restricted stock units?

Loerop’s 97,700 restricted stock units vest in four equal installments. Vesting occurs on the first, second, third, and fourth anniversaries of February 2, 2026, provided he satisfies the continuous service requirements under the company’s plan.

How do the Aclaris (ACRS) stock options granted to James Loerop vest over time?

The 341,900 employee stock options become exercisable in four equal installments. Vesting occurs on each of the first four anniversaries of February 2, 2026, conditioned on James Loerop maintaining continuous service as defined in the applicable plan.

Does the Aclaris (ACRS) Form 4 show James Loerop’s ownership as direct or indirect?

The Form 4 shows both the restricted stock units and the employee stock options as directly owned by James Loerop. No indirect ownership entities or disclaimers of beneficial ownership are indicated in the reported transactions or related footnotes.